BR112016014881A8 - usos de uma célula b de coelho, de pelo menos uma parte funcional do domínio extracelular de uma proteína e de um veículo de dispensa de genes, métodos para obtenção de uma cultura de célula b ex vivo, para aumentar a vida útil replicativa de uma célula b de coelho e para obtenção de anticorpos, e, anticorpo - Google Patents

usos de uma célula b de coelho, de pelo menos uma parte funcional do domínio extracelular de uma proteína e de um veículo de dispensa de genes, métodos para obtenção de uma cultura de célula b ex vivo, para aumentar a vida útil replicativa de uma célula b de coelho e para obtenção de anticorpos, e, anticorpo Download PDF

Info

Publication number
BR112016014881A8
BR112016014881A8 BR112016014881A BR112016014881A BR112016014881A8 BR 112016014881 A8 BR112016014881 A8 BR 112016014881A8 BR 112016014881 A BR112016014881 A BR 112016014881A BR 112016014881 A BR112016014881 A BR 112016014881A BR 112016014881 A8 BR112016014881 A8 BR 112016014881A8
Authority
BR
Brazil
Prior art keywords
cell
rabbit
vivo
methods
antibody
Prior art date
Application number
BR112016014881A
Other languages
English (en)
Other versions
BR112016014881B1 (pt
BR112016014881A2 (pt
Inventor
Helden Pauline Maria Wilhelmina Van
Mark Jeroen Kwakkenbos
Hergen Spits
Tim Beaumont
Original Assignee
Aimm Therapeutics Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aimm Therapeutics Bv filed Critical Aimm Therapeutics Bv
Publication of BR112016014881A2 publication Critical patent/BR112016014881A2/pt
Publication of BR112016014881A8 publication Critical patent/BR112016014881A8/pt
Publication of BR112016014881B1 publication Critical patent/BR112016014881B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0635—B lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1018—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/04—Immortalised cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13045—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6045—RNA rev transcr viruses
    • C12N2810/6054—Retroviridae

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

a presente invenção provê meios e métodos para a produção melhorada de cultura de célula b ex vivo com curto tempo de duplicação.
BR112016014881-9A 2013-12-24 2014-12-24 Métodos para obtenção de uma cultura de célula b ex vivo, para aumentar a vida útil replicativa de uma célula b de coelho e para obtenção de anticorpos, e, uso in vitro de pelo menos uma parte funcional do domínio extracelular de uma proteína galv e de um veículo de dispensa de genes BR112016014881B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13199584 2013-12-24
EP13199584.7 2013-12-24
PCT/NL2014/050908 WO2015099534A1 (en) 2013-12-24 2014-12-24 Ex vivo antibody production

Publications (3)

Publication Number Publication Date
BR112016014881A2 BR112016014881A2 (pt) 2017-08-08
BR112016014881A8 true BR112016014881A8 (pt) 2020-06-09
BR112016014881B1 BR112016014881B1 (pt) 2023-03-28

Family

ID=49885067

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016014881-9A BR112016014881B1 (pt) 2013-12-24 2014-12-24 Métodos para obtenção de uma cultura de célula b ex vivo, para aumentar a vida útil replicativa de uma célula b de coelho e para obtenção de anticorpos, e, uso in vitro de pelo menos uma parte funcional do domínio extracelular de uma proteína galv e de um veículo de dispensa de genes

Country Status (15)

Country Link
US (2) US20170009205A1 (pt)
EP (2) EP3087177B1 (pt)
JP (1) JP6832705B2 (pt)
CN (1) CN106029873A (pt)
AU (1) AU2014370516B9 (pt)
BR (1) BR112016014881B1 (pt)
CA (1) CA2934660C (pt)
DK (1) DK3087177T3 (pt)
EA (1) EA201691112A1 (pt)
ES (1) ES2927905T3 (pt)
HU (1) HUE060145T2 (pt)
IL (1) IL246409B (pt)
MX (1) MX2016008345A (pt)
SG (1) SG11201605126YA (pt)
WO (1) WO2015099534A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6013356B2 (ja) * 2010-12-02 2016-10-25 アイム・セラピューティクス・べー・フェー 高親和性抗体を製造するための手段および方法
CN116554353B (zh) * 2023-04-28 2024-05-03 北京奇迈永华生物科技有限公司 一种假病毒高效感染人nk细胞及其他免疫细胞的方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4343708B2 (ja) * 2002-04-26 2009-10-14 アンスティテュ ナシナル ドゥ ラ サントゥ エ ドゥ ラ ルシェルシェ メディカル−イ．エヌ．エス．ウ．エール．エム． 改良型キメラ糖タンパク質と、類型化されたレンチウイルス
WO2007019223A1 (en) * 2005-08-03 2007-02-15 Therapeutic Human Polyclonals, Inc. Suppression of b-cell apoptosis in transgenic animals expressing humanized immunoglobulin
PL2540820T3 (pl) * 2005-12-09 2018-05-30 Academisch Medisch Centrum Bij De Universiteit Van Amsterdam Środki i sposoby wpływania na stabilność komórek wytwarzających przeciwciała
EP2400298B1 (en) * 2010-05-28 2013-08-14 F.Hoffmann-La Roche Ag Single B-cell cultivation method and specific antibody production
JP6013356B2 (ja) * 2010-12-02 2016-10-25 アイム・セラピューティクス・べー・フェー 高親和性抗体を製造するための手段および方法
RU2017127486A (ru) * 2011-11-23 2019-02-06 Ф. Хоффманн-Ля Рош Аг Клетки млекопитающих, экспрессирующие лиганд cd40l, и их применение
WO2014109696A1 (en) * 2013-01-10 2014-07-17 Alf Grandien Method for immortalization of b cells and uses thereof
WO2015115892A1 (en) * 2014-01-31 2015-08-06 Aimm Therapeutics B.V. Means and methods for producing stable antibodies

Also Published As

Publication number Publication date
IL246409B (en) 2022-01-01
SG11201605126YA (en) 2016-07-28
NZ722156A (en) 2021-08-27
EP4141108A1 (en) 2023-03-01
US20170009205A1 (en) 2017-01-12
AU2014370516A1 (en) 2016-07-07
DK3087177T3 (da) 2022-10-03
MX2016008345A (es) 2017-02-08
ES2927905T3 (es) 2022-11-11
CN106029873A (zh) 2016-10-12
EA201691112A1 (ru) 2017-01-30
CA2934660A1 (en) 2015-07-02
EP3087177A1 (en) 2016-11-02
HUE060145T2 (hu) 2023-02-28
AU2014370516B9 (en) 2021-07-29
AU2014370516B2 (en) 2021-03-11
CA2934660C (en) 2023-03-14
EP3087177B1 (en) 2022-09-14
BR112016014881B1 (pt) 2023-03-28
IL246409A0 (en) 2016-08-31
BR112016014881A2 (pt) 2017-08-08
US20200149007A1 (en) 2020-05-14
JP2017500052A (ja) 2017-01-05
JP6832705B2 (ja) 2021-02-24
WO2015099534A1 (en) 2015-07-02

Similar Documents

Publication Publication Date Title
CY1122123T1 (el) Συνθεσεις λιπιδικου νανοσωματιδιου και μεθοδοι για απελευθερωση mrna
CY1121862T1 (el) Αντισωματα anti-phf-tau και χρησεις αυτων
AR103161A1 (es) Anticuerpos antimiostatina y regiones fc variantes así como métodos de uso
CO2017006651A2 (es) Anticuerpos anti-c5
CY1121217T1 (el) Μεθοδοι για συγκομιδη καλλιεργειων κυτταρου θηλαστικων
EA201991369A1 (ru) Модифицированные направляющие рнк
CL2018001577A1 (es) Anticuerpos anti-c5 y métodos de uso
CR20150284A (es) Terapia de combinación de anticuerpos anti-her3 y anti-her2
UY32501A (es) Anticuerpo antagonista específico para el heterodímero alfa4-beta7
CL2018003573A1 (es) Anticuerpos anti-c5 y métodos de uso.
EA201591817A1 (ru) Не содержащая сыворотки среда для культивирования клеток
BR112016025519A2 (pt) engenharia genética in vivo com vetores de adenovírus
BR112017004614A2 (pt) terapias de combinação com anticorpos anti-cd38
CO6781491A2 (es) Anticuerpos del cea
CY1121243T1 (el) Χρηση μιας λαμινινης για τη διαφοροποιηση πλειοδυναμων κυτταρων σε κυτταρικες σειρες ηπατοκυτταρων
GB2538216A (en) Method of screening candidate biochemical entities targeting a target biochemical entity
CY1122612T1 (el) Μεθοδος
EA201690171A1 (ru) Улучшенный способ получения моноклональных антител
BR112015024553A2 (pt) anticorpo multiespecífico, anticorpo isolado, ácido nucleico isolado, célula hospedeira, método de produção de anticorpo, imunoconjugado, formulação farmacêutica, uso de anticorpo e método de tratamento de indivíduos com distúrbio
EA201592269A1 (ru) Способы и композиции для снижения иммуносупрессии опухолевыми клетками
AR080873A1 (es) Anticuerpos contra factor de crecimiento epidermico (anti-erbb3 o anti-her3)
CY1119602T1 (el) Συνθεσεις και μεθοδοι για παραγωγη γλυκοπρωτεϊνων
AR095348A1 (es) Medios de cultivo celular y métodos de producción de anticuerpos
BR112012020491A2 (pt) processo para a preparação de forma alfa de mesilato de imatinib.
BR112014032677A2 (pt) ensaios rápido para ativação de célula t por medições de rna usando citometria de fluxo

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B25G Requested change of headquarter approved

Owner name: AIMM THERAPEUTICS B.V. (NL)

B25A Requested transfer of rights approved

Owner name: KLING BIOTHERAPEUTICS B.V. (NL)

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 24/12/2014, OBSERVADAS AS CONDICOES LEGAIS